There are currently 977 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Cognitive Training Intervention and Attitudes Towards Genetics
NCT03094026
Recruiting
A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/08/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cognitive Impairment, Hematologic Neoplasms, Hematopoietic Cell Transplant
Register for Updates
ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA
NCT05004051
Recruiting
This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, using ViTAA (The Sponsor) aortic mapping technology.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: UAB - University of Alabama in Birmingham Hospital, Birmingham, Alabama
Conditions: Abdominal Aortic Aneurysms
Register for Updates
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
NCT04511078
Recruiting
The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/30/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Head and Neck Cancer
Register for Updates
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
NCT04660760
Recruiting
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stop... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Register for Updates
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: University of Alabama at Birmingham Site Number : 1230, Birmingham, Alabama
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Register for Updates
Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.
NCT05798481
Recruiting
The purpose of the study is to increase the in vivo levels of nitric oxide by generating nitric oxide donor compound S-nitrosoacetylcysteine (SNOAC) using the mixture of sodium nitrite and N-acetylcysteine crystals in the sublingual space. The generated SNOAC rapidly diffuses into blood circulation thereby decrease the systemic blood pressure. This compound can be an alternative to organic nitrate NO donor drugs without developing tolerance in patients.
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
03/27/2024
Locations: Anesthesiology and Perioperative Medicine, Birmingham, Alabama
Conditions: Hypertension, Cardiovascular Diseases
Register for Updates
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
NCT04971720
Recruiting
Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death. Natriuretic Peptides (NPs) are hormones produced by the heart which directly regulate BP by causing dilation of blood vessels and by removing sodium and water from the body. NPs have a 24-hour day-night rhythm and this controls the day-night rhythm of BP as well. The NP-BP rhythm relationship is b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
Register for Updates
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
NCT05006729
Recruiting
The University of Texas Health Science Center at San Antonio (UTHSCSA) will serve as the site for the RURAL Study Coordinating Center, led by PI Vasan Ramachandran, MD. The primary function of the Study Coordinating Center (SCC) is to serve as an administrative liaison between all of the RURAL study's cores. The SCC schedules, facilitates, and hosts, all RURAL meetings including preparation for Observational Study Monitoring Board (OSMB) meetings, and maintains direct communication with the stu... Read More
Gender:
All
Ages:
Between 25 years and 64 years
Trial Updated:
03/26/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Rural Health, Pulmonary Disease, Heart Diseases
Register for Updates
BeFit Toolbox Collaboration: Building Empowerment Through Fitness
NCT06293846
Recruiting
This project will identify the causative behavioral factors in low-income African American women leading to sedentarism, a major source of morbidity in HABD communities. Working with our partner, WUCN, we will engage with women in HABD housing to develop and (later) deliver a physical activity education program (BeFit) customized for this population.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Low-Income Population, Women's Health
Register for Updates
Functional Outcomes From Diets in Multiple Sclerosis
NCT05327322
Recruiting
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS). The investigators will also explore the how the diet interventions impact inflammation, immunity, and metabolic biomarkers.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama
Conditions: NASH, Cirrhosis, Liver
Register for Updates
Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)
NCT03771508
Recruiting
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
Gender:
All
Ages:
All
Trial Updated:
03/20/2024
Locations: Birmingham Gastroenterology Associates, Birmingham, Alabama
Conditions: Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
Register for Updates